Kymera Therapeutics Inc. (KYMR)

Market Closed

1 Sep, 20:00

NASDAQ (NMS)

119. 12

+0.31

+0.2609%

9.77B Market Cap

- P/E Ratio

- Div Yield

1.01M Volume

-2.54 Eps

$ 118.81

Previous Close

Investors:

+38

Add Transaction

Day Range

116.28 119.78

Year Range

39.84 130.05

Want to track KYMR and more in your Portfolio? 🎯

Get Started For Free

KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study

Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.

Zacks | 2 months ago

Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seekingalpha | 3 months ago

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration

Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.

Zacks | 4 months ago

Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript

Seekingalpha | 4 months ago

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug

Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.

Zacks | 4 months ago

Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders

Kymera Therapeutics remains a "Strong Buy", driven by positive phase 1b data for KT-621 in atopic dermatitis and pipeline expansion. KT-621 achieved a mean 63% EASI reduction and 40% pruritus NRS reduction, supporting advancement into phase 2b BROADEN2 [AD] and BREADTH [asthma] trials. Both AD and asthma programs received FDA Fast Track Designation, with mid-2027 [BROADEN2] and late-2027 [BREADTH] data readouts as key milestones.

Seekingalpha | 4 months ago

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200

Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.

Zacks | 4 months ago

Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seekingalpha | 5 months ago

Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss

Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into the clinic.

247wallst | 5 months ago

Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase

Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million in FY25, reflecting aggressive advancement of KT-621 and KT-579 into mid-stage trials, prioritizing long-term value over near-term profitability. KT-621's Phase 2b trials in atopic dermatitis and eosinophilic asthma are key 2027 catalysts; KT-579's Phase 1 data in autoimmune diseases is expected in 2H26.

Seekingalpha | 6 months ago

Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway

KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.

Zacks | 6 months ago

Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript

Seekingalpha | 6 months ago

Blog Affiliate Program About Terms Privacy Help Contact Us